Oncotype DX® breast cancer test achieves positive reimbursement in Switzerland

Genomic Health announced that starting on January 1, 2015, the Oncotype DX breast cancer test will be covered in Switzerland through the mandatory health insurance system. This means that patients with early-stage, hormone receptor-positive, HER2 negative, invasive breast cancer with up to three positive lymph nodes will have access to the Oncotype DX breast cancer test to help determine whether they are likely to benefit from chemotherapy in addition to hormonal therapy.

View PDF

Find an actor

Alpine High-Tech Venture Forum 201823.10.2018

The event will take place on 23 October 2018 in Lausanne

BioAlps Networking Day 2018

L'événement aura lieu le 29 novembre 2018 au blueFACTORY à Fribourg
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn